Bronchiectasis Market Set to Accelerate With Innovative Therapies

The bronchiectasis market is entering a transformative phase as rising disease awareness, improved diagnostic capabilities, and substantial unmet treatment needs create opportunities for innovative therapies. The growing pipeline includes targeted anti-inflammatory agents, bacteriophage-based treatments, nebulized therapies, and other novel mechanisms designed to address the underlying causes of disease progression rather than focusing solely on symptom control. Promising candidates such as Verducatib (BI 1291583), AP-PA02, ARINA-1 (RVN-301), and several other investigational therapies are expected to influence treatment strategies across the major markets over the coming decade.

Explore the evolving bronchiectasis treatment landscape and pipeline therapies today : https://www.delveinsight.com/report-store/bronchiectasis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Bronchiectasis Market Overview and Key Insights

According to DelveInsight's latest analysis, the bronchiectasis market across the 7MM was valued at approximately USD 1.6 billion in 2025. The United States represented the largest share of the treatment market, followed by the EU4 countries, the United Kingdom, and Japan. The overall market is anticipated to expand considerably through 2036, supported by the introduction of disease-focused therapies and increasing recognition of bronchiectasis as a significant chronic respiratory condition.

In 2025, the 7MM had nearly 1 million diagnosed prevalent cases of non-cystic fibrosis bronchiectasis (NCFB), with the patient population expected to increase during the forecast period. Meanwhile, diagnosed prevalent cases of cystic fibrosis-related bronchiectasis exceeded 80,000 during the same year. The expanding diagnosed population, combined with the need for therapies capable of reducing exacerbations and slowing disease progression, is likely to support market expansion.

Discover Insmed BRINSUPRI FDA approval status bronchiectasis 2025 @ https://www.delveinsight.com/sample-request/bronchiectasis-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Major Factors Supporting Bronchiectasis Market Expansion

The increasing prevalence of bronchiectasis and other chronic respiratory disorders is one of the primary factors contributing to market growth. Recurrent infections, chronic airway inflammation, impaired mucus clearance, COPD, cystic fibrosis, and other underlying conditions can contribute to disease development and progression. Improvements in disease awareness and diagnostic testing are also helping identify patients who may previously have remained undiagnosed.

Another major development has been the introduction of BRINSUPRI (brensocatib), which represents an important advancement in NCFB management. The therapy is positioned as the first FDA-approved DPP1 inhibitor and the first targeted treatment specifically approved for non-cystic fibrosis bronchiectasis. Its arrival provides a disease-focused therapeutic option for a population that has historically relied heavily on supportive care and off-label treatments.

The pipeline is also becoming increasingly diverse. Verducatib (BI 1291583), AP-PA02, ARINA-1 (RVN-301), HSK31858, CHF 6333, CSL787, GSK3862995, and other candidates are investigating different biological pathways and treatment strategies. Such diversification could create a more competitive market and provide physicians with additional options based on patient characteristics.

Evolving Bronchiectasis Treatment Landscape

Historically, bronchiectasis treatment has centered on symptom management, airway clearance, infection control, and prevention of exacerbations. Bronchodilators may be used to address airflow-related symptoms, while antibiotics play an important role in managing recurrent bacterial infections. Inhaled antibiotics, including therapies targeting Pseudomonas aeruginosa, may be particularly relevant for patients with chronic airway colonization.

However, many conventional approaches do not directly address the biological mechanisms responsible for ongoing airway inflammation and structural damage. This limitation has increased interest in targeted therapies capable of modifying important disease pathways.

Treatment selection is generally individualized according to disease severity, underlying etiology, microbial characteristics, exacerbation history, and comorbidities. The emergence of targeted therapies could gradually shift bronchiectasis management from predominantly supportive care toward more mechanism-based treatment.

Promising Pipeline Therapies Reshaping the Market

Boehringer Ingelheim's Verducatib (BI 1291583) is an investigational DPP1, or cathepsin C, inhibitor being developed for bronchiectasis. By inhibiting DPP1 activity, the therapy aims to reduce the activation of neutrophil serine proteases and subsequently limit neutrophil-mediated inflammation. This mechanism could potentially reduce airway injury, improve mucus characteristics, and support better disease control. Verducatib has received Breakthrough Therapy Designation and Fast Track Designation from the US FDA, with Breakthrough Therapy Designation granted in 2024. A Phase III study was initiated in July 2025 to further evaluate its safety and efficacy.

Armata Pharmaceuticals is developing AP-PA02, an inhaled bacteriophage cocktail targeting Pseudomonas aeruginosa. The therapy uses multiple bacteriophages designed to recognize different bacterial receptors, potentially offering broad activity against relevant bacterial strains. Positive topline results from the Phase II Tailwind study announced in December 2024 supported continued development of this approach in patients with NCFB.

Renovion's ARINA-1 (RVN-301) represents another innovative approach. The nebulized therapy is designed for at-home administration and aims to support mucus clearance, improve lung function, reduce airway inflammation, and potentially limit bacterial proliferation. Positive Phase II CLIMB results announced in April 2024 encouraged further development, with a Phase III program planned for NCFB and enrollment expected to begin in the third quarter of 2026.

Recent Bronchiectasis Market Developments

The competitive environment continued to advance during 2026. In July, Revagenix announced dosing of the first participant in a Phase I study of Rev-56, an inhaled anti-Pseudomonas therapy intended for patients with NCFB. In June, EMBARC announced a collaboration with Insmed to evaluate brensocatib 25 mg in bronchiectasis.

In May 2026, Infex Therapeutics reported encouraging Phase IIa dose-ranging results for RESP-X (INFEX702), an investigational anti-virulence monoclonal antibody for patients with NCFB colonized by Pseudomonas aeruginosa. Earlier, in February 2026, the UK MHRA granted marketing authorization for BRINSUPRI for patients aged 12 years and older with NCFB who experienced at least two flare-ups or worsening symptoms during the previous year.

Bronchiectasis Epidemiology Outlook

The epidemiological burden of bronchiectasis is expected to remain an important driver of market growth. In the United States, diagnosed prevalent NCFB cases in 2025 were concentrated primarily within the moderate-severity segment, which accounted for more than 160,000 cases. Mild and severe disease categories represented additional portions of the patient population.

DelveInsight's epidemiological assessment covers the 2022–2036 period across the United States, EU4, the United Kingdom, and Japan. The analysis includes diagnosed prevalent NCFB cases, gender- and severity-specific populations, etiology-specific cases, microbiological characteristics, cystic fibrosis-related bronchiectasis cases, age-specific CFB populations, and total treated bronchiectasis cases.